MNKD 6.66 (+1.52%)
US56400P7069BiotechnologyBiotechnology

MannKind (MNKD) Stock Highlights

6.66 | +1.52%
2024-09-19 02:41:02
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Statistics

Range Today
6.56 6.81
Volume Today 1.85M
Range 1 Year
3.17 6.68
Volume 1 Year 669.05M
Range 3 Year
2.49 6.68
Volume 3 Year 2.51B
Range 10 Year
0.67 39.4
Volume 10 Year 7.16B

Highlights

Market Capitalization 1.72B (small)
Floating Shares 268.88M
Current Price 6.66
Price To Earnings 125.2
Price To Revenue 7.28
Earnings Per Share 0.05
Payout Ratio 0%

Performance

Latest +1.52%
1 Month +28.57%
3 Months +39.92%
6 Months +49.33%
1 Year +49.66%
3 Years +52.75%
5 Years +375.71%
10 Years -78.79%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.